Mercedes Camacho1, Adriana Agüero2, Anna Sumarroca2, Laura López3, Miguel-Ángel Pavón4,5, Francesc-Xavier Avilés-Jurado6, Jacinto García2, Miquel Quer2, Xavier León7,8. 1. Laboratory of Angiology, Vascular Biology and Inflammation, Institute of Biomedical Research (IIB Sant Pau), Barcelona, Spain. 2. Otorhinolaryngology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, C/Mas Casanovas, 90, 08041, Barcelona, Spain. 3. Pathology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. 4. Infections and Cancer Laboratory, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain. 5. Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain. 6. Otorhinolaryngology Department, Hospital Clínic, Barcelona, Spain. 7. Otorhinolaryngology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, C/Mas Casanovas, 90, 08041, Barcelona, Spain. xleon@santpau.cat. 8. Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain. xleon@santpau.cat.
Abstract
INTRODUCTION: Tumor-infiltrating lymphocytes (TILs) have a recognized antitumor activity in head and neck squamous cell carcinoma (HNSCC). CD45 is one of the most highly expressed proteins in lymphocytes. We carry out a study to assess the prognostic value of transcriptional expression of CD45 in HNSCC. MATERIAL AND METHODS: We determined the transcriptional expression of CD45 in 160 consecutive HNSCC patients and compared the TIL values according to the CD45 expression. RESULTS: Five-year disease-free survival for patients with a high transcriptional expression of CD45 (n = 107) was 62.4% and for patients with a low expression (n = 53) it was 36.2% (P = 0.003). Patients with a high expression of CD45 had a better local recurrence-free survival and disease-specific survival. The results of a multivariate analysis showed that patients with a low expression of CD45 had 2.0-fold high risk of recurrence (95% CI 1.2-3.2, P = 0.003). In oropharyngeal carcinomas, HPV-positive tumors showed a higher transcriptional CD45 expression than HPV-negative tumors. Tumors with high CD45 expression had immunohistochemical TIL scores significantly higher than those with low CD45 expression. CONCLUSION: According to our results, CD45 expression is a potential marker for tumor outcome in HNSCC patients.
INTRODUCTION:Tumor-infiltrating lymphocytes (TILs) have a recognized antitumor activity in head and neck squamous cell carcinoma (HNSCC). CD45 is one of the most highly expressed proteins in lymphocytes. We carry out a study to assess the prognostic value of transcriptional expression of CD45 in HNSCC. MATERIAL AND METHODS: We determined the transcriptional expression of CD45 in 160 consecutive HNSCC patients and compared the TIL values according to the CD45 expression. RESULTS: Five-year disease-free survival for patients with a high transcriptional expression of CD45 (n = 107) was 62.4% and for patients with a low expression (n = 53) it was 36.2% (P = 0.003). Patients with a high expression of CD45 had a better local recurrence-free survival and disease-specific survival. The results of a multivariate analysis showed that patients with a low expression of CD45 had 2.0-fold high risk of recurrence (95% CI 1.2-3.2, P = 0.003). In oropharyngeal carcinomas, HPV-positive tumors showed a higher transcriptional CD45 expression than HPV-negative tumors. Tumors with high CD45 expression had immunohistochemical TIL scores significantly higher than those with low CD45 expression. CONCLUSION: According to our results, CD45 expression is a potential marker for tumor outcome in HNSCC patients.
Entities:
Keywords:
CD45; Head and neck squamous cell carcinoma; Immune infiltrate; Transcriptional expression; Tumor-infiltrating lymphocytes
Authors: Neil L Berinstein; Gregory T Wolf; Paul H Naylor; Lorraine Baltzer; James E Egan; Harvey J Brandwein; Theresa L Whiteside; Lynn C Goldstein; Adel El-Naggar; Cecile Badoual; Wolf-Herve Fridman; J Michael White; John W Hadden Journal: Cancer Immunol Immunother Date: 2011-11-06 Impact factor: 6.968
Authors: M Tabachnyk; L V R Distel; M Büttner; G G Grabenbauer; E Nkenke; R Fietkau; D Lubgan Journal: Oral Oncol Date: 2012-02-21 Impact factor: 5.337
Authors: Samer Rajjoub; Suzanne R Basha; Eugene Einhorn; Marc C Cohen; Doug M Marvel; Duane A Sewell Journal: Ear Nose Throat J Date: 2007-08 Impact factor: 1.697
Authors: E Zancope; N L Costa; A P Junqueira-Kipnis; M C Valadares; T A Silva; C R Leles; E F Mendonça; A C Batista Journal: J Oral Pathol Med Date: 2009-09-14 Impact factor: 4.253
Authors: Cecilia Nordfors; Nathalie Grün; Nikolaos Tertipis; Andreas Ährlund-Richter; Linnea Haeggblom; Lars Sivars; Juan Du; Tommy Nyberg; Linda Marklund; Eva Munck-Wikland; Anders Näsman; Torbjörn Ramqvist; Tina Dalianis Journal: Eur J Cancer Date: 2013-04-06 Impact factor: 9.162
Authors: Anders Näsman; Mircea Romanitan; Cecilia Nordfors; Nathalie Grün; Hemming Johansson; Lalle Hammarstedt; Linda Marklund; Eva Munck-Wikland; Tina Dalianis; Torbjörn Ramqvist Journal: PLoS One Date: 2012-06-12 Impact factor: 3.240